Activated PI3K Delta Syndrome (APDS)
A rare primary immunodeficiency caused by overactive PI3K-delta signaling, leading to recurrent infections, lymphoproliferation, and an increased risk of lymphoma.
- Primary immunodeficiency disorder
- Targeted PI3K-delta inhibitor therapy
- Lymphoma surveillance access
- Typical Age at Onset
- Childhood
- Inheritance
- Autosomal dominant (PIK3CD or PIK3R1)
- Key Risk
- Recurrent infections; lymphoma risk
- Advanced Therapies
- Targeted PI3K-delta inhibitor (leniolisib)
What Is Activated PI3K Delta Syndrome (APDS)?
Activated PI3K delta syndrome (APDS) is a rare inherited primary immunodeficiency caused by mutations that overactivate the PI3K-delta signaling pathway in immune cells. This overactivity disrupts normal B and T cell development and function, leading to recurrent sinopulmonary infections, enlarged lymph nodes and spleen, and an increased risk of lymphoma.
Two genetic forms are recognized: APDS1, caused by gain-of-function mutations in PIK3CD, and APDS2, caused by loss-of-function mutations in PIK3R1, which encodes a regulatory subunit of the same pathway. Both forms produce a broadly similar clinical picture, though APDS2 has additionally been associated with some growth and developmental features in certain patients.
APDS was only formally characterized in the past decade, and the discovery of a targeted PI3K-delta inhibitor has changed the treatment landscape for many patients, offering an option beyond general immunoglobulin replacement and infection management.
Genetic Subtypes of APDS
APDS is divided into two genetically distinct but clinically overlapping forms.
Symptoms and Signs
Most patients present in childhood with recurrent infections and progressive lymphoid enlargement.
Causes and Risk Factors
APDS is caused by inherited mutations that disrupt normal regulation of a key immune cell signaling pathway.
Diagnosis and Investigations
Diagnosis combines immune function testing with genetic confirmation of the underlying mutation.
Disease Risk Stratification
APDS is not formally staged, but disease burden is tracked based on infection frequency, lymphoproliferation, and evidence of malignant transformation.
Standard Treatment Approach
Management combines infection prevention, immune support, and, where appropriate, targeted pathway-specific therapy.
Advanced and Emerging Treatment Options
APDS is notable among primary immunodeficiencies for having an approved targeted molecular therapy.
Targeted Therapy
PI3K-Delta Inhibitor (Leniolisib)
An oral targeted inhibitor approved for APDS that directly addresses the overactive signaling pathway, improving immune function and reducing lymphoproliferation in clinical studies.
Cellular Therapy
Allogeneic Hematopoietic Stem Cell Transplant
Considered for severe or refractory disease, particularly when complicated by lymphoma, and can be curative for the underlying immune defect.
Immunotherapy
Immunoglobulin Replacement Therapy
Reduces bacterial infection burden in patients with significant antibody deficiency.
Precision Medicine
Genetic Subtype-Guided Management
Confirming APDS1 versus APDS2 helps anticipate associated features and supports family counseling.
Biomarkers and Precision Medicine
Genetic and immune function findings guide treatment selection and monitoring.
When a Second Opinion May Be Important
Because APDS is rare and recently characterized, specialist input can meaningfully change management.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in APDS have improved with better recognition and the availability of targeted therapy. Many patients achieve good control of infections and lymphoproliferation, though lifelong surveillance for lymphoma and other complications remains important.
Supportive Care and Living With APDS
Day-to-day management focuses on infection prevention and consistent specialist monitoring.
How CancerFax Helps You Explore Treatment Options
We help families with APDS access specialist review of immune and genetic reports, connect with experienced immunology centers, and coordinate second opinions on targeted therapy or transplant options.
Get a free case reviewFrequently Asked Questions
APDS is a rare inherited primary immunodeficiency caused by overactivity of the PI3K-delta signaling pathway, leading to recurrent infections, lymphoproliferation, and an increased lymphoma risk.
APDS1 is caused by gain-of-function mutations in PIK3CD, while APDS2 is caused by loss-of-function mutations in PIK3R1; both affect the same signaling pathway and produce a similar clinical picture.
Recurrent sinus and lung infections along with persistently enlarged lymph nodes are common early signs, typically appearing in childhood.
Yes, it is inherited in an autosomal dominant pattern, though some cases arise from a new mutation without a family history.
Diagnosis combines immunoglobulin and lymphocyte testing with genetic confirmation of a PIK3CD or PIK3R1 mutation.
Yes, an oral PI3K-delta inhibitor has been approved that directly addresses the overactive signaling pathway underlying APDS.
Yes, APDS carries an increased lifetime risk of lymphoma, which is why regular surveillance of lymph nodes is important.
Transplant is generally reserved for severe or refractory disease, particularly when complicated by lymphoma, rather than being used for all patients.
Monitoring frequency depends on disease severity, but typically includes regular clinical evaluation and periodic imaging of lymph nodes.
Yes. CancerFax can help you arrange specialist review of medical and genetic reports, connect with experienced immunology centers, and coordinate second opinions on targeted therapy or transplant options for APDS.
Get Specialist Guidance for APDS
Send your reports for review and explore targeted therapy and second-opinion options with experienced specialists.